Study guide

3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA)

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA)

Key Takeaways Explain This Topic AI

Sanger sequencing remains a gold-standard orthogonal method for known single-variant confirmation and small amplicon questions, but it is inefficient as a first-line genome-wide diagnostic.

NGS gene panels offer deep coverage of curated genes matched to phenotype; they still have coverage gaps, limited structural-variant detection, and panel-content obsolescence risk.

WES targets mostly coding sequence; WGS sequences broadly across the genome and improves some structural and noncoding detection—neither guarantees perfect sensitivity for all variant classes.

Secondary findings on exome/genome are a pretest counseling topic (ACMG secondary findings gene list concept); detail on return-of-results processes continues in later interpretation chapters.

MLPA and related dosage assays detect exon-level deletions/duplications that sequencing-only pipelines may miss when CNV calling is absent or limited.

Last updated: August 2026

Why molecular method literacy is a counseling skill

CGC exam stems rarely ask you to run a sequencer. They ask whether the ordered test can answer the clinical question , what it might miss, and what incidental information could return. Molecular methods differ in target space (one variant, a gene list, the exome, the genome), depth , CNV/structural sensitivity , and incidental finding potential . Choosing poorly wastes time, insurance authorization, and family trust.

Sanger sequencing

Sanger sequencing (chain-termination sequencing) reads a defined PCR amplicon at high accuracy for single-nucleotide variants and small insertions/deletions within that amplicon.

  • Strength Limitation
  • Excellent for confirming a known familial variant Poor throughput for large gene lists
  • Orthogonal validation of NGS calls when labs require it Does not interrogate unamplified regions
  • Useful for known hotspot / single-exon questions Allele dropout if primer binding site has a variant

Familiar for cascade testing of a reported variant Will not detect large deletions spanning primer sites without dosage methods

Clinical pattern: Use Sanger (or an equivalent targeted assay) when the familial pathogenic variant is already defined and you need relatives tested efficiently. Do not start an undiagnosed complex phenotype workup with “Sanger the whole genome”—that is not how Sanger works.

NGS gene panels

Next-generation sequencing (NGS) panels enrich or capture a curated set of genes related to a phenotype (cardiomyopathy panel, epilepsy panel, RASopathy panel, etc.), then sequence at typically high depth .

Advantages

Phenotype-matched content reduces some noise versus untargeted testing.

Deep coverage improves sensitivity for mosaic calls in some settings (still assay-dependent).

Often cheaper and faster than exome/genome with clearer coverage metrics for included genes.

Limitations boards love

  • Limitation Counseling language
  • Panel content Genes not on the panel are not tested—even if later evidence implicates them
  • Coverage gaps Homopolymers, high-GC regions, pseudogenes, and repetitive segments may have low/no coverage

Structural variants Many panels have limited or no reliable detection of large rearrangements unless CNV analysis is included and validated

Deep intronic / regulatory variants Usually outside panel design

Updates A “negative” 2018 panel may miss genes added to 2026 panels—reanalysis or broader testing may be warranted

Exam scenario: Phenotype strongly suggests a gene known to have frequent exon deletions; a sequencing-only panel without del/dup analysis is incomplete—add MLPA , targeted deletion analysis, or a platform with validated CNV calling.

Whole exome sequencing (WES)

WES targets the exome —roughly the ~1–2% of the genome that encodes proteins—plus some flanking bases, depending on kit design.

  • What WES does well What WES struggles with
  • Many Mendelian coding SNVs/indels Noncoding regulatory variants outside capture
  • Broader differential than a narrow panel Some exon-level CNVs (better if CNV pipeline included)

Discovery when phenotype is heterogeneous Pseudogenes / homologous regions; mitochondrial genome often separate

Trio exome (proband + parents) improves de novo/inheritance filters Incomplete coverage of some exons despite “exome” label

Coverage honesty: “Exome” does not mean every coding base is adequately covered. Labs issue coverage metrics and gene-level caveats; a critical exon with poor coverage may need Sanger fill-in.

Secondary findings preview

Exome and genome sequencing can reveal secondary findings —medically actionable variants in genes unrelated to the primary indication (classic framework: ACMG secondary findings gene list, updated periodically). Pretest counseling should cover:

That secondary findings may be analyzed and reported depending on lab policy and patient opt-in/opt-out rules.

That this is distinct from the primary diagnostic search.

That detailed classification, disclosure logistics, and family cascade planning continue in interpretation and results-delivery chapters.

For Domain 3A, remember the concept and counseling trigger , not every gene on the current ACMG list.

Whole genome sequencing (WGS)

WGS sequences across the genome (with platform-specific gaps) rather than capturing only exons.

Relative advantage vs WES Remaining limitations

Better access to noncoding and some structural variant signatures Short-read WGS still struggles with some repeats, highly homologous regions

More uniform coverage of many coding regions vs capture bias Interpretation burden; VUS volume; cost/authorization barriers

Improved detection of some CNVs/SVs with appropriate pipelines Mitochondrial and epigenetic disorders may need dedicated tests

Single assay sometimes replaces stepwise panel→exome cascades “Negative genome” ≠ “not genetic” for all mechanisms (imprinting, repeat expansions, etc.)

Teaching point: WGS is more comprehensive for many DNA sequence and structural questions than WES, but it is not omniscient. Match mechanism to method: fragile X–type repeat expansions , methylation disorders, and some RNA/protein assays still need specialized tests.

MLPA and dosage methods

MLPA (multiplex ligation-dependent probe amplification) detects copy-number changes at exon or gene resolution for targeted loci. Related approaches include quantitative PCR, chromosomal microarray for larger CNVs, and NGS-based CNV calling.

Use MLPA (or equivalent) when Do not assume

Gene has frequent exon del/dup architecture (classic teaching examples include dystrophinopathy deletion/duplication patterns, some hereditary cancer genes historically) Sequencing alone always catches dosage changes

A “negative” sequence test leaves del/dup untested MLPA surveys the whole genome

You need orthogonal confirmation of a suspected exon deletion MLPA replaces CMA for genome-wide pediatric CNV first-line evaluation

Method comparison table

  • Method Primary target Best for Classic miss
  • Sanger Single amplicon / known variant Confirmation; cascade testing Everything outside amplicons; large dels
  • NGS panel Curated gene set Focused phenotype with known gene set Off-panel genes; some SVs; coverage holes
  • WES Mostly coding genome Broad Mendelian differential Many noncoding/SV classes; coverage gaps

WGS Broad genome sequence Broader SV/noncoding reach; complex undiagnosed disease Some repeats/homology; non-sequence mechanisms

  • MLPA Targeted exon/gene dosage Del/dup at known loci Untargeted loci; balanced rearrangements
  • Building a molecular testing strategy

Define the variant class you must detect (SNV, indel, exon del/dup, balanced rearrangement, aneuploidy, repeat expansion).

Choose the narrowest adequate test that covers that class and the differential—then escalate if negative and suspicion remains.

Confirm whether the lab’s panel/exome/genome pipeline includes validated CNV analysis .

Counsel coverage limitations and secondary findings before send-out.

Plan orthogonal confirmation when management hinges on a single call (especially unexpected secondary findings or atypical variants).

Molecular literacy on the CGC exam is less about chemistry and more about what the report cannot see .